Diltiazem Hydrochloride
Generic Details
Generic Name
Diltiazem Hydrochloride
Other Names
- Cardizem
- Diltiazem HCL
- Taztia
- Tiazac
Drug Class
- Calcium Channel Blocker
- Antiarrhythmic
Chemical Formula
C22H26N2O4S
Molecular Weight
414.52 g/mol
Mechanism of Action
- Inhibits calcium ion influx through L-type calcium channels in cardiac and smooth muscle cells, leading to vasodilation and decreased cardiac workload.
Indications
- Hypertension
- Angina pectoris
- Atrial fibrillation/flutter
- Supraventricular tachyarrhythmias
Common Dosage Forms
- Tablet
- Capsule
- Extended-release capsule
Typical Dosage
- 120-480 mg/day in divided doses for hypertension
- 180-360 mg/day in divided doses for angina
Pediatric Dosage
- Safety and efficacy not established in children
Geriatric Dosage
- May require lower initial doses due to age-related reductions in hepatic and renal function
Side Effects
- Dizziness
- Headache
- Edema
- Constipation
- Bradycardia
- Hypotension
- Flushing
Contraindications
- Sick sinus syndrome
- 2nd or 3rd-degree AV block
- Hypotension
- Severe heart failure
Pregnancy Category
- Category C - Safety in pregnancy has not been established, potential benefits may warrant its use
Lactation Safety
- Limited data available, caution advised
Drug Interactions
- Simvastatin
- Beta-blockers
- Cyclosporine
- Digoxin
Overdose Symptoms
- Hypotension
- Bradycardia
- Cardiac conduction disturbances
Antidote for Overdose
- Calcium chloride or calcium gluconate for severe hypotension or cardiac conduction abnormalities
Storage Conditions
- Store at room temperature away from moisture and heat
Pharmacokinetics
- Absorption: Rapidly absorbed after oral administration
- Distribution: Highly protein-bound, distributed extensively into tissues
- Metabolism: Extensively metabolized in the liver via CYP3A4
- Excretion: Excreted mainly in the urine as metabolites
Precautions
- Monitor blood pressure and heart rate regularly
- Avoid abrupt withdrawal to prevent rebound hypertension or angina
Warnings
- Do not crush or chew extended-release formulations
- Avoid grapefruit juice due to CYP3A4 interactions
Others
- May be used off-label for Raynaud's phenomenon